516 results on '"Vogelmeier, Claus F."'
Search Results
2. Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET
3. GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists
4. Gold 2023: Highlights for primary care
5. In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
6. Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD
7. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
8. A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
9. Impact of COPD on mortality: An 8-year observational retrospective healthcare claims database cohort study
10. Potential systemic effects of acquired CFTR dysfunction in COPD
11. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities
12. COPD and multimorbidity: recognising and addressing a syndemic occurrence
13. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
14. Diagnostic Performance of a Machine Learning Algorithm (Asthma/Chronic Obstructive Pulmonary Disease [COPD] Differentiation Classification) Tool Versus Primary Care Physicians and Pulmonologists in Asthma, COPD, and Asthma/COPD Overlap
15. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
16. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
17. Association of coronary artery calcification with clinical and physiological characteristics in patients with COPD: Results from COSYCONET
18. A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic
19. Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD
20. Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function
21. Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET
22. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment
23. IgE is associated with exacerbations and lung function decline in COPD
24. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
25. Cardiovascular predictors of mortality and exacerbations in patients with COPD
26. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
27. Differential Impact of Low Fat-Free Mass in People With COPD Based on BMI Classifications: Results From the COPD and Systemic Consequences-Comorbidities Network
28. COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort
29. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
30. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial
31. Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
32. Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis
33. Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease
34. COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development
35. Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET.
36. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET
37. Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort
38. Goals of COPD treatment: Focus on symptoms and exacerbations
39. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
40. Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
41. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
42. CAT score single item analysis in patients with COPD: Results from COSYCONET
43. COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study
44. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials
45. NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
46. SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
47. Early Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease: The Costs and Benefits of Case Finding.
48. A mRNA panel for differentiation between acute exacerbation or pneumonia in COPD patients.
49. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
50. Left ventricular volume and wall stress are linked to lung function impairment in COPD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.